What Limits Primary Emulsion Stability in PURASORB PDLG 7507 Microsphere Production?

Because PDLG 7507 is a 75:25 poly(DL-lactide-co-glycolide) with acid-terminated chain ends, the primary water-in-oil emulsion used for peptide-loaded microspheres is more sensitive to inner aqueous-phase pH and buffer composition than an ester-terminated analogue. The organic phase is prepared by dissolving the copolymer in dichloromethane at 10–25% w/w and mixing with a concentrated aqueous drug solution at a drug-to-polymer mass ratio ranging from 1:5 to 1:20. Emulsion formation is carried out with a rotor-stator homogenizer or in-line high-shear mixer at 5,000–15,000 rpm while the primary vessel is held at 2–8 °C. At oil-phase concentrations above 20% w/w, the organic-phase viscosity rises sufficiently to shift primary droplet size from roughly 1–5 µm to 10–30 µm when the same tip speed is maintained, creating a process conflict between throughput and particle-size control. The primary emulsion is then transferred into an aqueous continuous phase containing 0.5–2% w/w poly(vinyl alcohol) with a hydrolysis degree of 87–89%, and dichloromethane is extracted under stirred conditions at 5–10 °C for 2–4 h. Terminal finished product type is a sterile lyophilized microsphere powder for reconstitution in an aqueous diluent before intramuscular or subcutaneous administration. Compliance for injectable microspheres is assessed through USP <71> sterility, USP <85> bacterial endotoxins, USP <790> visible particulate matter, ISO 10993-1:2018 biological evaluation, and ISO 13485:2016 quality management; residual dichloromethane is measured against the 6 mg/day permitted daily exposure in ICH Q3C(R8). Production-scale equipment typically includes a 50–100 L jacketed reactor with bottom-drain filtration or a solvent-extraction vessel for 1–5 kg batch sizes. Observed failure modes on such lines include particle coalescence when quench temperature exceeds 15 °C, residual solvent retention above 0.1% w/w when hardening time is shortened below 2 h, and bottom-drain filter blinding if the primary emulsion is transferred before droplet hardening. Pre-drying of PDLG 7507 at 2–5 mbar and 25–30 °C for 12–24 h is required if the container has been opened for more than 1 h at relative humidity above 60%; absorbed moisture lowers molecular weight during terminal processing and alters organic-phase viscosity. Amine-based buffers in the inner aqueous phase must be avoided because they neutralize the acid chain ends and modify in vitro release kinetics.

When PURASORB PDLG 7507 is formulated as an in situ forming depot, the polymer solution is prepared by dissolution in N-methyl-2-pyrrolidone or dimethyl sulfoxide at 30–50% w/w, and the active pharmaceutical ingredient is dissolved or suspended at 1–10% w/w in the final solution. Terminal finished product type is a sterile polymer solution supplied in a single-dose prefilled syringe or vial for insertion into a delivery device, where the depot solidifies by solvent exchange after subcutaneous or intramuscular injection. Compliance for an injectable solution is established through USP <71>, USP <85>, USP <787> subvisible particulates, ISO 10993-4:2017 blood compatibility, and ISO 10993-5:2009 cytotoxicity. N-methyl-2-pyrrolidone residual content follows ICH Q3C(R8) with a permitted daily exposure of 53 mg/day; dimethyl sulfoxide is monitored against its 50 mg/day limit when used. The phase-inversion rate is governed by solvent-water miscibility and polymer-solvent affinity; because N-methyl-2-pyrrolidone is fully water-miscible, depot skin formation occurs within seconds to minutes, while the core remains solvent-rich and can produce a burst release above 20–30% in the first 24 h if the injection depth is insufficient or the polymer concentration is below 30% w/w. Increasing PDLG 7507 content to 45–50% w/w reduces burst but raises solution viscosity sufficiently that a 23G needle or wider may be required, and injection force can exceed 15 N when the solution is conditioned at 2–8 °C rather than room temperature. In manufacturing, dissolution is performed in a jacketed glass or stainless steel vessel under vacuum and nitrogen overlay at 25–40 °C for 12–24 h, followed by passage through a 40–100 µm mesh or depth filter rather than a sterilizing-grade membrane because the high-viscosity solution is not filterable through 0.22 µm at scale. Terminal sterilization may use gamma irradiation at 25–40 kGy with dry ice or inert atmosphere; published data for this specific configuration is limited, and each lot must be evaluated for molecular weight retention because the acid-terminated copolymer is more susceptible to irradiation-induced chain scission than higher molecular weight ester-terminated grades.

Hot-Melt Extrusion Limits for Acid-Terminated 75:25 PLGA Implant Rods

For a monolithic implant rod, PURASORB PDLG 7507 is dry-blended with a heat-stable active pharmaceutical ingredient at 5–50% w/w drug load, while the copolymer occupies 60–95% w/w of the formulation; triethyl citrate or polyethylene glycol 1500 may be added at 0–10% w/w to lower melt viscosity. Terminal finished product type is a monolithic subcutaneous implant rod or cylinder, typically 1.0–2.0 mm in diameter and 1–3 cm in length, packaged in a needle-based trocar or insertion device. Compliance for a solid implant is anchored to ISO 10993-6:2016 implantation testing, ISO 10993-5:2009 cytotoxicity, ASTM F1635-16 in vitro degradation, and USP <905> content uniformity. Extrusion is carried out on a twin-screw extruder with an L/D ratio of 24:1 to 40:1, barrel temperatures of 85–105 °C, screw speed of 20–100 rpm, and melt pressure of 20–80 bar; the polymer must be pre-dried to 0.2% w/w moisture or below before entering the barrel. The glass transition temperature of this copolymer is reported between 45 °C and 55 °C depending on residual solvent and molecular weight, so barrel settings are above the glass transition but below 120 °C, where autocatalytic degradation of the acid-terminated 75:25 PLGA accelerates. A narrow processing window exists in practice: if barrel temperature exceeds 110 °C, the melt shows torque decline, yellowing, and molecular weight loss indicating chain scission; if temperature remains below 85 °C, melt viscosity is too high and die pressure can exceed 90 bar, triggering shutdown or strand breakage. The extrudate is pelletized or cut to length after air cooling, then sealed in moisture-barrier packaging under nitrogen. Published data for this specific configuration is limited; the operating limits above are derived from supplier technical bulletins and peer-reviewed PLGA extrusion studies. The acid-terminated end groups create an additional incompatibility with amine-based additives, which can accelerate molecular weight reduction during extrusion, and with high levels of hydrophilic plasticizer above 10% w/w, which can phase-separate and lower tensile strength below the values required for trocar insertion.

When the copolymer is nanoprecipitated below 40 °C from a water-miscible solvent, the resulting nanoparticle dispersion is typically filtered through a 0.22 µm sterilizing-grade membrane before lyophilization, provided the mean particle size remains below 200 nm and the polydispersity index remains below 0.2. The organic phase is prepared by dissolving PDLG 7507 in acetone, acetonitrile, or ethyl acetate at 5–20 mg/mL, while the active pharmaceutical ingredient is included at a drug-to-polymer mass ratio of 1:10 to 1:20; the aqueous phase contains poly(vinyl alcohol) or vitamin E TPGS at 0.1–2% w/w as a colloidal stabilizer. Terminal finished product type is a sterile lyophilized nanosuspension or nanoparticle cake for intravenous or locoregional injection after reconstitution. Compliance for this dosage-form intermediate is assessed through ISO 10993-5:2009 cytotoxicity, USP <787> subvisible particulate matter, and ICH Q3C(R8) for residual acetone or acetonitrile; acetone is limited to 50 mg/day and acetonitrile to 4.1 mg/day. In manufacturing, mixing is performed by dropwise addition or through a microfluidic cartridge with controlled flow-rate ratios, followed by solvent removal under reduced pressure or tangential flow filtration. Lyophilization is carried out with trehalose or mannitol at 2–5% w/w as a cryoprotectant, and the freeze-dried cake is reconstituted to a particle size that must be re-verified after storage. The main operational boundary is solvent selection: residual dichloromethane is difficult to remove from nanoparticles below 200 nm and must be avoided unless downstream gas chromatography can demonstrate compliance with the 6 mg/day limit. Particle size increases when the aqueous phase temperature is allowed to rise above 40 °C during mixing, and batch-to-batch variance in particle size is more pronounced with dropwise addition than with controlled microfluidic mixing.

The Solvent-Cast Drying Rate Controls Drug Distribution in Resorbable Films

In solvent-cast film manufacturing, the drying parameter rather than the initial solution viscosity often determines whether a drug remains molecularly dispersed or recrystallizes within the PLGA matrix. PDLG 7507 is dissolved in dichloromethane or ethyl acetate at 5–15% w/w, the active pharmaceutical ingredient is loaded at 1–10% w/w of the dry film mass, and polyethylene glycol 400 may be added at 0–15% w/w to reduce brittleness. Terminal finished product type is a sterile resorbable drug-eluting film or surgical adhesion barrier supplied in double-peel pouches. Compliance is tested against ISO 10993-5:2009 cytotoxicity, ISO 10993-10:2021 sensitization, ASTM D882-18 tensile properties, and USP <905> content uniformity. The casting solution is applied to a polyester release liner at a controlled thickness of 200–800 µm, then dried at 20–35 °C for 4–12 h under an airflow rate below 0.5 m/s; immediately after, the film is transferred to a vacuum oven at 2–5 mbar and 25–35 °C for 24–48 h to reduce residual solvent. When the initial airflow exceeds 0.5 m/s, the surface vitrifies and traps solvent beneath the film skin, producing bubbles, uneven drug distribution, and residual dichloromethane above 600 ppm. Residual dichloromethane is therefore monitored by gas chromatography against the ICH Q3C(R8) permitted daily exposure of 6 mg/day; ethyl acetate is preferred when the drug is soluble in ethyl acetate because its permitted daily exposure is 50 mg/day. The finished film is die-cut or laser-cut to the required dimensions, checked for release liner peel force, and terminally sterilized by gamma irradiation at 25–40 kGy under nitrogen. A formulation boundary exists with drugs that have low glass-transition or melting temperatures: drying above 35 °C can cause the drug to partition to the film surface, and subsequent content uniformity failures are observed across the cut film.

A drug-eluting stent coating based on PDLG 7507 is prepared from a low-solids solution containing the copolymer at 1–5% w/w in acetone, tetrahydrofuran, or chloroform, with the active pharmaceutical ingredient at a drug-to-polymer mass ratio of 1:1 to 1:5. Terminal finished product type is a balloon-expandable or self-expanding metallic stent platform with a conformal PLGA drug-eluting coating of 2–10 µm thickness. Compliance for this combination product includes ISO 10993-4:2017 hemocompatibility, ISO 10993-5:2009 cytotoxicity, ISO 10993-6:2016 local effects after implantation, and USP <788> subvisible particulate matter in the final rinse solution. Coating is performed in a controlled-environment chamber with an ultrasonic spray nozzle operating at 40–120 kHz and a flow rate of 0.1–5 mL/min, while the stent rotates on a mandrel at 50–150 rpm; the chamber is held at 40–60 °C to flash residual solvent without causing surface blistering. Multiple passes are required to reach the target coating thickness, and the coated stent is vacuum-dried at 2–5 mbar and 25–35 °C for 24–48 h. Solvent choice is constrained by residual solvent limits: chloroform carries a permitted daily exposure of 0.6 mg/day under ICH Q3C(R8), tetrahydrofuran 7.2 mg/day, and acetone 50 mg/day. The operational boundary for PDLG 7507 in this application is the acid-terminated chain end: the coating solution must not be held for more than 24 h before spray application because slow hydrolysis in the solvent mixture can reduce molecular weight, lower coating toughness, and create delamination after stent expansion. Published data for this specific formulation is limited; batch release therefore requires scanning electron microscopy for coating continuity, differential scanning calorimetry for glass transition, and high-performance liquid chromatography for drug content and related substances.